Solarius Capital Acquisition Corp.
Filed Jun 16, 2025.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Jun 16, 2025
Contents
Cover page
Show cover page
S-11 solariuss1060625.htm FORM S-1
As filed with the U.S. Securities and Exchange Commission on June 16, 2025.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
*UNDER
THE SECURITIES ACT OF 1933*
(Exact name of registrant as specified in its charter)
| Cayman Islands | 6770 | N/A |
|---|---|---|
| (State or other jurisdiction of incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) |
PO Box 2248
Darien, Connecticut 06820
Tel: (203) 617-0223
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Richard H. Haywood, Jr.
Chief Executive Officer
PO Box 2248
Darien, Connecticut 06820
Tel: (203) 617-0223
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
| Daniel Nussen White & Case LLP 555 South Flower Street Suite 2700 Los Angeles, CA 90071 Tel: (213) 620-7700 | Joel L. Rubinstein White & Case LLP 1221 Avenue of the Americas New York, NY 10020 Tel: (212) 819-8200 | Daniel Lee Maples and Calder P.O. Box 309, Ugland House Grand Cayman KY1-1104 Cayman Islands Tel: (345) 949-8066 | Stephen P. Alicanti Sidney Burke DLA Piper LLP (US) 1251 Avenue of the Americas New York, NY 10020 Tel: (212) 335-4500 |
|---|
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☒ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED JUNE 13, 2025
PRELIMINARY PROSPECTUS
$150,000,000
15,000,000 Units
Solarius Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us.
This is an initial public offering of our securities. Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as described herein. We refer to the warrants included in the units as public warrants. Only whole warrants are exercisable. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The warrants will become exercisable 30 days after the completion of our initial business combination, and will expire five years after the completion of our initial business combination or earlier upon redemption or our liquidation, as described herein. The underwriters have a 45-day option from the date of this prospectus to purchase up to an additional 2,250,000 units to cover over-allotments, if any.
We will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares that were sold as part of the units in this offering, which we refer to collectively as our public shares, in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account described below as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. As further described in this prospectus, our amended and restated memorandum and articles of association will provide that a public shareholder, together with any affiliate or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended), will be restricted from redeeming its public shares with respect to more than an aggregate of 15% of the public shares, without our prior consent.
If we are unable to complete our initial business combination within 21 months from the closing of this offering, or such other time period in which we must complete an initial business combination pursuant to an amendment to our amended and restated memorandum and articles of association, which we refer to as the completion window, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain conditions as further described herein. We may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension.
Our sponsor, Solarius Capital Sponsor, LLC, has committed to purchase an aggregate of 450,000 private placement units, at $10.00 per unit for an aggregate purchase price of $4,500,000, in a private placement that will close simultaneously with the closing of this offering. Each private placement unit consists of one Class A ordinary share and one-half of one warrant, as described in more detail in this prospectus. These units, which we refer to as the private placement units, are identical to the units sold in this offering, subject to limited exceptions as described in this prospectus.
Our sponsor currently owns an aggregate of 5,750,000 Class B ordinary shares, which we refer to as the founder shares throughout this prospectus. The founder shares were purchased for $25,000, or approximately $0.004 per share. The sponsor will surrender up to 750,000 of the founder shares to us for no consideration after the closing of this offering depending on the extent to which the underwriters’ over-allotment option is exercised. The Class B ordinary shares will automatically convert into Class A ordinary shares immediately prior to, concurrently with or immediately following the consummation of our initial business combination or earlier at the option of the holder on a one-for-one basis, subject to the adjustments described herein. After taking into account the issuance of the private placement shares, our sponsor will own an aggregate of 5,450,000 ordinary shares, or 26.7% of our issued and outstanding ordinary shares immediately following the completion of this offering assuming the over-allotment option is not exercised, or an aggregate of 6,200,000 ordinary shares, or 26.4% of our issued and outstanding ordinary shares immediately following the completion of this offering, assuming the over-allotment option is exercised in full. If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 25% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares included in the private placement units and the Class A ordinary shares underlying the warrants included in the private placement units). Prior to the closing of our initial business combination, only holders of our Class B ordinary shares will be entitled to vote on the appointment and removal of directors or continuing the company in a jurisdiction outside the Cayman Islands (including any special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents of the Company, in each case, as a result of the Company approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). On any other matters submitted to a vote of our shareholders prior to or in connection with the completion of our initial business combination, holders of the Class B ordinary shares and holders of the Class A ordinary shares will vote together as a single class, except as required by law. See the sections entitled “Summary — Our Sponsor” on page 11, “Summary — The Offering — Founder Shares” on page 19, “Summary — The Offering — Founder Shares Conversion and Anti-Dilution Rights” on page 21, “Summary — The Offering — Voting” on page 21, “Risk Factors — The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares and the amount of the deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us” on page 38, “Risk Factors — We may issue additional Class A ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. We may also issue Class A ordinary shares upon the conversion of the founder shares at a ratio greater than one-to-one at the time of our initial business combination as a result of the anti-dilution provisions contained therein. Any such issuances would dilute the interest of our shareholders and likely present other risks” on page 48, “Dilution” on page 77 and “Proposed Business — Our Sponsor” on page 91 for more information.
Currently, there is no public market for our units, Class A ordinary shares or warrants. We have applied to have our units listed on The Nasdaq Global Market, or Nasdaq, under the symbol “SOCAU.” We expect that our shares will be listed on Nasdaq on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq; however, we will not consummate this offering if our securities are not approved for listing on Nasdaq. We expect the Class A ordinary shares and warrants that comprise the units to begin separate trading on the 52 nd day following the date of this prospectus unless Stifel, Nicolaus & Company, Incorporated, the representative of the underwriters, informs us of its decision to allow earlier separate trading, subject to our satisfaction of certain conditions as described further herein. Once the securities comprising the units begin separately trading, we expect that the Class A ordinary shares and warrants will be listed on Nasdaq under the symbols “SOCA” and “SOCAW” respectively.
We are an “emerging growth company” and a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public company reporting requirements. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 37 for a discussion of information that should be considered in connection with an investment in our securities. Investors will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings.
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. No offer or invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities.
| Per Unit | Total | |
|---|---|---|
| Public offering price | $10.00 | $150,000,000 |
| Underwriting discounts and commissions(1) | $0.60 | $9,000,000 |
| Proceeds, before expenses, to us | $9.40 | $141,000,000 |
| (1) | Includes 2.0% of the gross proceeds of this offering, excluding the gross proceeds pursuant to the underwriters’ over-allotment option, payable to the underwriters upon the closing of this offering in the form of a cash underwriting discount. In addition, the underwriters have agreed to defer underwriting commissions of 4.0% of the gross proceeds of this offering (excluding the gross proceeds pursuant to the exercise of the underwriters’ over-allotment option) and 6.0% of the gross proceeds pursuant to the exercise of the underwriters’ over-allotment option. Upon and concurrently with the completion of our initial business combination, up to $6,000,000 (or up to $7,350,000 if the underwriters’ over-allotment option is exercised in full), which constitutes the underwriters’ deferred commissions, will be paid to the underwriters from the funds held in the trust account as follows: (i) a cash payment of $2,000,000 and (ii) up to $4,000,000 (or up to $5,350,000 if the underwriters’ over-allotment option is exercised in full) of the aggregate gross proceeds of this offering, representing the remaining deferred commissions, which will be reduced based on the percentage of total funds from the trust account released to pay redeeming shareholders. See also “Underwriting” for a description of compensation and other items of value payable to the underwriters and for a description of reimbursements for expenses the underwriters have agreed to pay us at the closing of this offering. |
Of the proceeds we receive from this offering and the sale of the private placement units described in this prospectus, $150,750,000, or $173,362,500 if the underwriters’ over-allotment option is exercised in full ($10.05 per share in either case), will be deposited into a trust account located in the United States with Continental Stock Transfer & Trust Company acting as trustee, after deducting $3,000,000 in underwriting discounts and commissions payable upon the closing of this offering and an aggregate of $2,250,000 (or up to $2,362,500 if the underwriters’ over-allotment option is exercised in full), inclusive of underwriter reimbursements, and will be available to pay fees and expenses in connection with the closing of this offering and for working capital following the closing of this offering.
Because our sponsor acquired the founder shares at a nominal aggregate price of $25,000, or approximately $0.004 per share, our public shareholders will incur an immediate and material dilution upon the closing of this offering. Further, the Class A ordinary shares issuable in connection with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti-dilution rights of our founder shares that may result in an issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion.See the section titled “Risk Factors — The nominal purchase price paid by our sponsor for the founder shares may significantly dilute the implied value of your public shares in the event we consummate an initial business combination, and our sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline” on page 64 and “— We may issue additional Class A ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. We may also issue Class A ordinary shares upon the conversion of the founder shares at a ratio greater than one-to-one at the time of our initial business combination as a result of the anti-dilution provisions contained therein. Any such issuances would dilute the interest of our shareholders and likely present other risks” on page 48. We will also pay our sponsor for office and administrative services provided to members of our management team in an amount equal to $30,000 per month. Our sponsor may loan us up to $400,000 under an unsecured, non-interest bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2025 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $750,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions. Our sponsor or an affiliate of our sponsor or certain of our officers and directors may loan us funds to finance transaction costs in connection with an intended initial business combination. Such loans may be convertible into private placement units of the post-business combination entity at a price of $10.00 per unit at the option of the lender. The issuance of such shares may result in material dilution to our public shareholders.See the section titled “Summary — Our Sponsor” for more information regarding, among other things, the amount of compensation and securities received or to be received by our sponsor, its affiliates and our officers and directors.
The following table illustrates the difference between the public offering price and our net tangible book value per share, as adjusted to reflect various potential redemption levels that may occur in connection with the closing of our initial business combination, which we refer to as Adjusted NTBVPS, on a pro forma basis to give effect to this offering and the issuance of the private placement units, assuming no exercise of the over-allotment option and exercise of the over-allotment option in full. Adjusted NTBVPS excludes the effect of the consummation of our initial business combination or any related transactions or expenses.See the section titled “Dilution” for more information.
| As of April 4, 2025 | ||||||||
|---|---|---|---|---|---|---|---|---|
| Offering Price of $10.00 · 25% of Maximum Redemption · 50% of Maximum Redemption · 75% of Maximum Redemption · Maximum Redemption | ||||||||
| Adjusted NTBVPS | Adjusted NTBVPS | Difference between Adjusted NTBVPS and Offering Price | Adjusted NTBVPS | Difference between Adjusted NTBVPS and Offering Price | Adjusted NTBVPS | Difference between Adjusted NTBVPS and Offering Price | Adjusted NTBVPS | Difference between Adjusted NTBVPS and Offering Price |
| Assuming No Exercise of Over-Allotment Option | ||||||||
| $7.12 | $6.47 | $3.53 | $5.44 | $4.56 | $3.57 | $6.43 | $(0.87) | $10.87 |
| Assuming Full Exercise of Over-Allotment Option | ||||||||
| $7.13 | $6.47 | $3.53 | $5.44 | $4.56 | $3.56 | $6.44 | $(0.94) | $10.94 |
Members of our management team will directly or indirectly own founder shares and/or private placement units following this offering and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Further, each of our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors were to be included by a target business as a condition to any agreement with respect to our initial business combination. The low price that our sponsor, executive officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. If we are unable to complete our initial business combination within the completion window, the founder shares may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. Additionally, each of our officers and directors presently has, and any of them in the future may have additional, fiduciary or contractual obligations to another entity pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, there may be actual or potential material conflicts of interest between our sponsor, its affiliates or promoters on the one hand, and the investors in this offering on the other hand.See the sections titled “Proposed Business — Sourcing of Potential Business Combination Targets” and “Management — Conflicts of Interest.”
The underwriters are offering the units for sale on a firm commitment basis. The underwriters expect to deliver the units to the purchasers on or about , 2025.
Sole Book-Running Manager
Stifel
, 2025
TABLE OF CONTENTS
| Page | |
|---|---|
| Summary | 1 |
| Summary Financial Data | 36 |
| Risk Factors | 37 |
| Cautionary Note Regarding Forward-Looking Statements | 74 |
| Use of Proceeds | 75 |
| Dividend Policy | 77 |
| Dilution | 77 |
| Capitalization | 80 |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations | 81 |
| Proposed Business | 85 |
| Management | 116 |
| Principal Shareholders | 126 |
| Certain Relationships and Related Party Transactions | 129 |
| Description of Securities | 131 |
| Taxation | 148 |
| Underwriting | 158 |
| Legal Matters | 164 |
| Experts | 164 |
| Where you can Find Additional Information | 164 |
We have not, and the underwriters have not, authorized anyone to provide you with information that is different from or inconsistent with that contained in this prospectus. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus.
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.